HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry.
Fabienne FröhlichRaphael MicheroliMonika HebeisenSeraphina KisslingKristina BürkiPascale ExerRené BrämKarin NiedermannBurkhard MöllerMichael J NissenDiego KyburzMichael AndorOliver DistlerAlmut SchererAdrian CiureaPublished in: Clinical rheumatology (2022)
The HLA-B27 genotype is an important predictor of treatment effectiveness. Male sex and CRP seem, however, to better describe variability of response in individual patients. This data may help avoiding potential discrimination of B27- individuals with regard to TNFi initiation. Key Points • HLA-B27 is a predictor of effectiveness of TNF inhibitors in axial spondyloarthritis. • Variability of response in individual patients is better defined by sex and objective markers of disease activity, such as C-reactive protein.
Keyphrases
- disease activity
- rheumatoid arthritis
- end stage renal disease
- randomized controlled trial
- ankylosing spondylitis
- ejection fraction
- systemic lupus erythematosus
- systematic review
- newly diagnosed
- chronic kidney disease
- prognostic factors
- electronic health record
- peritoneal dialysis
- big data
- machine learning
- climate change
- patient reported